Cargando…

Clinical Efficacy of Ruxolitinib in Patients with Myelofibrosis: A Nationwide Population-Based Study in Korea

Previous studies have reported the survival benefit after ruxolitinib treatment in patients with myelofibrosis (MF). However, population-based data of its efficacy are limited. We analyzed the effects of ruxolitinib in MF patients with data from the Korean National Health Insurance Database. In tota...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Byung-Hyun, Moon, Hyemi, Chae, Jae-Eun, Kang, Ka-Won, Kim, Byung-Soo, Lee, Juneyoung, Park, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8540308/
https://www.ncbi.nlm.nih.gov/pubmed/34682897
http://dx.doi.org/10.3390/jcm10204774
_version_ 1784588955727953920
author Lee, Byung-Hyun
Moon, Hyemi
Chae, Jae-Eun
Kang, Ka-Won
Kim, Byung-Soo
Lee, Juneyoung
Park, Yong
author_facet Lee, Byung-Hyun
Moon, Hyemi
Chae, Jae-Eun
Kang, Ka-Won
Kim, Byung-Soo
Lee, Juneyoung
Park, Yong
author_sort Lee, Byung-Hyun
collection PubMed
description Previous studies have reported the survival benefit after ruxolitinib treatment in patients with myelofibrosis (MF). However, population-based data of its efficacy are limited. We analyzed the effects of ruxolitinib in MF patients with data from the Korean National Health Insurance Database. In total, 1199 patients diagnosed with MF from January 2011 to December 2017 were identified, of which 731 were included in this study. Patients who received ruxolitinib (n = 224) were matched with those who did not receive the drug (n = 507) using the 1:1 greedy algorithm. Propensity scores were formulated using five variables: age, sex, previous history of arterial/venous thrombosis, and red blood cell (RBC) or platelet (PLT) transfusion dependence at the time of diagnosis. Cox regression analysis for overall survival (OS) revealed that ruxolitinib treatment (hazard ratio (HR), 0.67; p = 0.017) was significantly related to superior survival. In the multivariable analysis for OS, older age (HR, 1.07; p < 0.001), male sex (HR, 1.94; p = 0.021), and RBC (HR, 3.72; p < 0.001) or PLT (HR, 9.58; p = 0.001) transfusion dependence were significantly associated with poor survival, although type of MF did not significantly affect survival. Considering evidence supporting these results remains weak, further studies on the efficacy of ruxolitinib in other populations are needed.
format Online
Article
Text
id pubmed-8540308
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85403082021-10-24 Clinical Efficacy of Ruxolitinib in Patients with Myelofibrosis: A Nationwide Population-Based Study in Korea Lee, Byung-Hyun Moon, Hyemi Chae, Jae-Eun Kang, Ka-Won Kim, Byung-Soo Lee, Juneyoung Park, Yong J Clin Med Article Previous studies have reported the survival benefit after ruxolitinib treatment in patients with myelofibrosis (MF). However, population-based data of its efficacy are limited. We analyzed the effects of ruxolitinib in MF patients with data from the Korean National Health Insurance Database. In total, 1199 patients diagnosed with MF from January 2011 to December 2017 were identified, of which 731 were included in this study. Patients who received ruxolitinib (n = 224) were matched with those who did not receive the drug (n = 507) using the 1:1 greedy algorithm. Propensity scores were formulated using five variables: age, sex, previous history of arterial/venous thrombosis, and red blood cell (RBC) or platelet (PLT) transfusion dependence at the time of diagnosis. Cox regression analysis for overall survival (OS) revealed that ruxolitinib treatment (hazard ratio (HR), 0.67; p = 0.017) was significantly related to superior survival. In the multivariable analysis for OS, older age (HR, 1.07; p < 0.001), male sex (HR, 1.94; p = 0.021), and RBC (HR, 3.72; p < 0.001) or PLT (HR, 9.58; p = 0.001) transfusion dependence were significantly associated with poor survival, although type of MF did not significantly affect survival. Considering evidence supporting these results remains weak, further studies on the efficacy of ruxolitinib in other populations are needed. MDPI 2021-10-18 /pmc/articles/PMC8540308/ /pubmed/34682897 http://dx.doi.org/10.3390/jcm10204774 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lee, Byung-Hyun
Moon, Hyemi
Chae, Jae-Eun
Kang, Ka-Won
Kim, Byung-Soo
Lee, Juneyoung
Park, Yong
Clinical Efficacy of Ruxolitinib in Patients with Myelofibrosis: A Nationwide Population-Based Study in Korea
title Clinical Efficacy of Ruxolitinib in Patients with Myelofibrosis: A Nationwide Population-Based Study in Korea
title_full Clinical Efficacy of Ruxolitinib in Patients with Myelofibrosis: A Nationwide Population-Based Study in Korea
title_fullStr Clinical Efficacy of Ruxolitinib in Patients with Myelofibrosis: A Nationwide Population-Based Study in Korea
title_full_unstemmed Clinical Efficacy of Ruxolitinib in Patients with Myelofibrosis: A Nationwide Population-Based Study in Korea
title_short Clinical Efficacy of Ruxolitinib in Patients with Myelofibrosis: A Nationwide Population-Based Study in Korea
title_sort clinical efficacy of ruxolitinib in patients with myelofibrosis: a nationwide population-based study in korea
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8540308/
https://www.ncbi.nlm.nih.gov/pubmed/34682897
http://dx.doi.org/10.3390/jcm10204774
work_keys_str_mv AT leebyunghyun clinicalefficacyofruxolitinibinpatientswithmyelofibrosisanationwidepopulationbasedstudyinkorea
AT moonhyemi clinicalefficacyofruxolitinibinpatientswithmyelofibrosisanationwidepopulationbasedstudyinkorea
AT chaejaeeun clinicalefficacyofruxolitinibinpatientswithmyelofibrosisanationwidepopulationbasedstudyinkorea
AT kangkawon clinicalefficacyofruxolitinibinpatientswithmyelofibrosisanationwidepopulationbasedstudyinkorea
AT kimbyungsoo clinicalefficacyofruxolitinibinpatientswithmyelofibrosisanationwidepopulationbasedstudyinkorea
AT leejuneyoung clinicalefficacyofruxolitinibinpatientswithmyelofibrosisanationwidepopulationbasedstudyinkorea
AT parkyong clinicalefficacyofruxolitinibinpatientswithmyelofibrosisanationwidepopulationbasedstudyinkorea